Aprea Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 7
- Market Cap
- $19.1M
- Website
- http://www.aprea.com
- Introduction
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
- Conditions
- Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
- Interventions
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 247
- Registration Number
- NCT02098343
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇫🇷Centre Léon Bérard, Lyon, France
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
- Conditions
- Hematologic NeoplasmsProstatic Neoplasms
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT00900614
- Locations
- 🇸🇪
Section of Haematology and Coagulation, Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, Sweden
🇸🇪Clinical Research and Development Unit, Department of Oncology, Akademiska Hospital, Uppsala, Sweden